Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 6, Pages 830
Publisher
MDPI AG
Online
2019-06-14
DOI
10.3390/cancers11060830
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Tyrosine Kinase Inhibitors (Tki) In Renal Cell Carcinoma: A Meta-Analysis Of Available Clinical Trials
- (2019) Francesco Massari et al. Clinical Genitourinary Cancer
- CheckMate 214 patient-reported outcomes: listening to our patients
- (2019) Francesco Massari et al. LANCET ONCOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
- (2019) Veronica Mollica et al. CLINICAL DRUG INVESTIGATION
- Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis
- (2019) Vincenzo Di Nunno et al. Immunotherapy
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
- (2018) Ana M. Molina et al. EUROPEAN JOURNAL OF CANCER
- Tivozanib for the treatment of renal cell carcinoma
- (2018) Matteo Santoni et al. EXPERT OPINION ON PHARMACOTHERAPY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
- (2018) Christopher J. Ricketts et al. Cell Reports
- THE ROLE OF ENDOTHELIAL COLONY FORMING CELLS IN KIDNEY CANCER’S PATHOGENESIS, AND IN RESISTANCE TO ANTI-VEGFR AGENTS AND mTOR INHIBITORS: A SPECULATIVE REVIEW
- (2018) Valentina Poletto et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
- (2018) Vincenzo Di Nunno et al. Future Oncology
- Recommendations for the Management of Rare Kidney Cancers
- (2017) Rachel H. Giles et al. EUROPEAN UROLOGY
- Future perspectives for personalized immunotherapy in renal cell carcinoma
- (2017) Chiara Ciccarese et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer
- (2017) James J. Hsieh et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
- (2017) Alessandro Inno et al. TUMORI
- Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade
- (2017) Kei Ishibashi et al. Oncotarget
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
- (2017) Alessandro Inno et al. TUMORI JOURNAL
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma
- (2016) Tram Anh Tran et al. MOLECULAR AND CELLULAR BIOLOGY
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- A river model to map convergent cancer evolution and guide therapy in RCC
- (2015) Elizabeth Y. Wei et al. Nature Reviews Urology
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma
- (2014) Anthony J. Gill et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
- (2014) Matteo Santoni et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
- (2014) Caleb F. Davis et al. CANCER CELL
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
- (2014) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Third-line dovitinib in metastatic renal cell carcinoma
- (2014) Manuela Schmidinger LANCET ONCOLOGY
- Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
- (2014) Kwonoh Park et al. Cancer Research and Treatment
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reactive Oxygen Species via Redox Signaling to PI3K/AKT Pathway Contribute to the Malignant Growth of 4-Hydroxy Estradiol-Transformed Mammary Epithelial Cells
- (2013) Victor O. Okoh et al. PLoS One
- Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma
- (2012) María José Méndez-Vidal et al. CANCER AND METASTASIS REVIEWS
- Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
- (2012) Monica Bernal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
- (2012) Tim Eisen et al. LANCET ONCOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
- (2011) Ilya Tsimafeyeu et al. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
- (2010) D. J. Jonker et al. ANNALS OF ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells
- (2009) Eric Sulpice et al. BIOLOGY OF THE CELL
- Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α
- (2009) Robert A. Figlin et al. CANCER
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
- (2008) John D. Gordan et al. CANCER CELL
- Regulatory T Cells and Immune Tolerance
- (2008) Shimon Sakaguchi et al. CELL
- CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NFκB through the CBM (Carma3/Bcl10/Malt1) Complex
- (2008) Daniel Martin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation